Is IMUC a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,611 people get IMUC articles and Market Currents by email alert.

Get email alerts on IMUC »

HEADLINES:

ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on May 30th

Business Wire (Wed, 6:00AM)
ImmunoCellular Therapeutics Announces Issuance of Key Patent Covering ICT-107 Cancer Vaccine Target

Business Wire (Thu, 6:00AM)
3 Biotech Stocks With Potential
Equity Options Guru • Tue, May 14 • 9 Comments
Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 4 Comments
SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
ImmunoCellular Therapeutics: Marching Toward Top Line Data For ICT-107 In Q4 2013
Smith On Stocks • Fri, May 10 • 11 Comments
ImmunoCellular Therapeutics Announces First Quarter 2013 Financial Results

Business Wire (May 9, 2013)
Northwest Biotherapeutics: Moving DC Vax-L Rapidly Forward And Starting DC Vax Direct Trials
Smith On Stocks • Tue, May 7 • 61 Comments
Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trial
PropThink • Fri, May 3 • 33 Comments
With A New Institutional Investor On Board, Northwest Biotherapeutics Breaks The Curse
Andreas Spiro • Wed, May 1 • 12 Comments
ImmunoCellular Therapeutics to Report Financial Results for the First Quarter 2013 May 9, 2013

Business Wire (May 1, 2013)
An Industry Outlook With Analyst Vernon Bernardino
Brian Nichols • Mon, Apr 22 • 5 Comments
2 Undervalued Immunotherapy Picks
Amy Baldwin • Mon, Apr 15 • 28 Comments
The 9 Levels Of Biotechnology And Who Should Invest: Part 2
Brian Nichols • Mon, Apr 8 • 12 Comments
ImmunoCellular Therapeutics to Present at Future Leaders Conference on April 5th

Business Wire (Mar 28, 2013)
Biotechnology Super Panel Talks Development, Marketing And The Future
The Swiss Trader • Wed, Mar 27 • 8 Comments
ImmunoCellular Therapeutics: A Close Look At Key Issues For The Ongoing Phase II Trial Of ICT-107
Smith On Stocks • Wed, Mar 27 • 39 Comments
A Newbie Active Investor Discusses His Portfolio
Oneota Investor • Tue, Mar 19 • 97 Comments
The Weekend Blitz: Finding Value, Market Behavior, & Diversification Related Plays
Brian Nichols • Mon, Mar 18 • 18 Comments
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments

To learn more about Seeking Alpha Pro, click here.

ImmunoCellular Therapeutics: Marching Toward Top Line Data For ICT-107 In Q4 2013
Smith On Stocks • Fri, May 10 • 11 Comments
ImmunoCellular Therapeutics: A Close Look At Key Issues For The Ongoing Phase II Trial Of ICT-107
Smith On Stocks • Wed, Mar 27 • 39 Comments
ImmunoCellular Update Adds Clarity And Further Validates Investment Thesis
PropThink • Thu, Mar 7 • 8 Comments
Correctly Reading Cash Flows And Balance Sheets: ImmunoCellular Vs. Northwest Biotherapeutics
Richard Richter • Tue, Feb 26 • 25 Comments
A Look At ImmunoCellular Therapeutics Just Prior To Interim Data
Brian Nichols • Tue, Feb 12 • 45 Comments
ImmunoCellular Shares Near Lows Offer A Speculative Oncology Play
PropThink • Tue, Dec 4, 2012 • 8 Comments
ImmunoCellular Therapeutics: An Opportunity For Great Upside Potential
Demetri Mallios • Wed, Nov 21, 2012 • 29 Comments
ICT-107 Into Perspective: Part 2
Brian Nichols • Tue, Aug 28, 2012 • 75 Comments
ImmunoCellular CEO Steps Down But Leaves Company Well Positioned
Brian Nichols • Mon, Aug 20, 2012 • 56 Comments
ICT-107 Into Perspective: Part 1
Brian Nichols • Wed, Aug 15, 2012 • 16 Comments
Dr. Keith Black Talks ICT-107
Brian Nichols • Tue, Aug 14, 2012 • 9 Comments
ImmunoCellular Therapeutics: Explaining The Benefits Of A Multiple Antigen Targeting Approach
Brian Nichols • Mon, Jul 23, 2012 • 23 Comments
New Legislation Speeds Up FDA Approval Process for ImmunoCellular Therapeutics And Other Innovating Therapies
Brian Nichols • Thu, Jul 19, 2012 • 35 Comments
Intellectual Property Of A Biotech: An Analysis
Chemistfrog • Wed, Jul 11, 2012 • 5 Comments
ImmunoCellular: Cancer Is Smart, But Could An Experimental Cancer Vaccine Be Smarter?
A John Hodge • Wed, Jun 27, 2012 • 4 Comments
ImmunoCellular Therapeutics ICT-107 To Impress At ASCO 2012
Chemistfrog • Fri, Jun 1, 2012 • 8 Comments
ImmunoCellular Therapeutics' Uplisting To NYSE Could Immediately Open Many Doors
Brian Nichols • Tue, May 29, 2012 • 8 Comments
Interest Growing In Cancer Stem Cell Biotechs
A John Hodge • Mon, May 21, 2012 • 5 Comments
Hitting The Jackpot With Small-Cap Bio Pharma Investment, Part 3: The Immune System
Scott Matusow • Wed, May 16, 2012 • 69 Comments
Pre-ASCO Interview With ImmunoCellular Therapeutics CEO Dr. Singh
Brian Nichols • Thu, May 10, 2012 • 16 Comments

3 Biotech Stocks With Potential
Equity Options Guru • Tue, May 14 • 9 Comments
Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 4 Comments
SmithOnStocks Opines On Recent Biotech News
Smith On Stocks • Mon, May 13 • 8 Comments
Northwest Biotherapeutics: Moving DC Vax-L Rapidly Forward And Starting DC Vax Direct Trials
Smith On Stocks • Tue, May 7 • 61 Comments
Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trial
PropThink • Fri, May 3 • 33 Comments
With A New Institutional Investor On Board, Northwest Biotherapeutics Breaks The Curse
Andreas Spiro • Wed, May 1 • 12 Comments
An Industry Outlook With Analyst Vernon Bernardino
Brian Nichols • Mon, Apr 22 • 5 Comments
2 Undervalued Immunotherapy Picks
Amy Baldwin • Mon, Apr 15 • 28 Comments
The 9 Levels Of Biotechnology And Who Should Invest: Part 2
Brian Nichols • Mon, Apr 8 • 12 Comments
Biotechnology Super Panel Talks Development, Marketing And The Future
The Swiss Trader • Wed, Mar 27 • 8 Comments
A Newbie Active Investor Discusses His Portfolio
Oneota Investor • Tue, Mar 19 • 97 Comments
The Weekend Blitz: Finding Value, Market Behavior, & Diversification Related Plays
Brian Nichols • Mon, Mar 18 • 18 Comments
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments
The Weekend Blitz: A Discussion Of Investment Strategies And Investment Ideas
Brian Nichols • Sun, Mar 10 • 16 Comments
2 Biotech Superstars For 2013
Equity Options Guru • Tue, Mar 5 • 30 Comments
A Comprehensive Look At Immunotherapy - Part 2
Brian Nichols • Mon, Mar 4 • 24 Comments
Northwest Biotherapeutics: My Rationale For Having A Buy Recommendation
Smith On Stocks • Mon, Feb 25 • 37 Comments
The Monday Morning Quarterback
Brian Nichols • Mon, Feb 25 • 12 Comments
Northwest Biotherapeutics: A Critique Of Adam Feuerstein Of TheStreet's Recent Analysis
Smith On Stocks • Tue, Feb 19 • 103 Comments
A Comprehensive Look At Immunotherapy With Analyst/Immunologist Dr. Rahul Jasuja
Brian Nichols • Fri, Feb 8 • 31 Comments

ImmunoCellular Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 5 • 1 Comment

ImmunoCellular Therapeutics to Present at Marcum MicroCap Conference on May 30th

Business Wire (Wed, 6:00AM)
ImmunoCellular Therapeutics Announces Issuance of Key Patent Covering ICT-107 Cancer Vaccine Target

Business Wire (Thu, 6:00AM)
ImmunoCellular Therapeutics Announces First Quarter 2013 Financial Results

Business Wire (May 9, 2013)
ImmunoCellular Therapeutics to Report Financial Results for the First Quarter 2013 May 9, 2013

Business Wire (May 1, 2013)
ImmunoCellular Therapeutics to Present at Future Leaders Conference on April 5th

Business Wire (Mar 28, 2013)
ImmunoCellular Therapeutics to Present at ROTH Conference on March 18th

Business Wire (Mar 11, 2013)
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2012 Financial Results

Business Wire (Mar 5, 2013)
ImmunoCellular Therapeutics Announces Issuance of Key Patent for ICT-121 Cancer Vaccine

Business Wire (Mar 4, 2013)
ImmunoCellular Therapeutics to Report Financial Results for the Fourth Quarter and Full Year 2012 on March 5, 2013

Business Wire (Feb 26, 2013)
ImmunoCellular Therapeutics to Present at BIO CEO & Investor Conference on February 11th

Business Wire (Feb 4, 2013)
ImmunoCellular Therapeutics’ Investigational New Drug (IND) Application for ICT-140 Allowed by the FDA

Business Wire (Jan 29, 2013)
ImmunoCellular Therapeutics Provides Update on Corporate Milestones

Business Wire (Jan 7, 2013)
ImmunoCellular Therapeutics Appoints Gary S. Titus to its Board of Directors

Business Wire (Jan 2, 2013)
ImmunoCellular Therapeutics Appoints Andrew Gengos as Chief Executive Officer

Business Wire (Dec 3, 2012)
ImmunoCellular Therapeutics Reports Third Quarter 2012 Financial Results

Business Wire (Nov 12, 2012)
ImmunoCellular Therapeutics to Present at Lazard Capital Markets 9th Annual Healthcare Conference on November 14th

Business Wire (Nov 5, 2012)
ImmunoCellular Therapeutics Provides an Update on Recent 2012 Achievements and Anticipated Milestones

Business Wire (Nov 1, 2012)
ImmunoCellular Therapeutics, Ltd. Announces Pricing of its Previously Announced Public Offering of Common Stock and Warrants

Business Wire (Oct 18, 2012)
ImmunoCellular Therapeutics, Ltd. Announces Proposed Public Offering of Common Stock and Warrants

Business Wire (Oct 17, 2012)
ImmunoCellular Therapeutics to Present at 3rd Annual Cancer Immunotherapy Conference and 2012 BIO Investor Forum

Business Wire (Oct 2, 2012)

IMUC vs. ETF Alternatives

Company Description

ImmunoCellular Therapeutics, Ltd., a development stage company, focuses on developing and commercializing therapeutics to treat cancer using the immune system. Its product candidate portfolio consists of cellular immunotherapies targeting cancer and cancer stem cell antigens; peptide based... More

Sector: Healthcare

Industry: Medical Instruments & Supplies

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 5:45 PM After-hours top gainers, as of 5:15 p.m.: PDII +26.9%. NSPH +20.1%. III +11.6%. TTWO +4.1%. NTI +2.9%.
After-hours top losers: MOSY -9.4%. ATAX -4.6%. SPH -4.3%. WES -3.9%. IMUC -3.6%. Comment! [On the Move]
Thursday, May 9, 6:04 PM ImmunoCellular (IMUC): Q1 EPS of -$0.10 misses by $0.02. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Wednesday, April 3, 5:35 PM After-hours top gainers, as of 5:15 p.m.: CCG +8%. ANV +5%. AVEO +4%. GFI +3%. VALE +2%.
After-hours top losers: SFUN -6%. IMUC -3%. CPWR -3%. LSE -3%. ROC -2%. Comment! [On the Move]
Thursday, March 7, 8:30 AM Northwest Biotherapeutics (NWBO +2%) expects to complete the enrollment of a 312-patient Phase III trial for its Glioblastoma multiforme brain cancer drug by Q1 or early Q2 next year. NW Bio says its recruitment is faster or more efficient than that for rival drugs, including for treatments from Celldex (CLDX), Immunocellular (IMUC) and Agenus (AGEN). (PR) 1 Comment [Healthcare]
Tuesday, March 5, 6:07 PM After-hours top gainers, as of 5:30 p.m.: HCI +11%. ELX +10%. HNR +8%. PAY +5%. BPZ +4%.
After-hours top losers: AVAV -22%. HLS -11%. NAVB -7%. JMBA -6%. IMUC -5%. Comment! [On the Move]
Tuesday, March 5, 4:34 PM ImmunoCellular Therapeutics (IMUC): Q4 EPS of -$0.01 beats by $0.07. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, March 4, 8:25 AM ImmunoCellular Therapeutics (IMUC) receives a patent covering its ICT-121 immunotherapeutic cancer vaccine, which targets CD133, an important cancer stem cell marker that is "commonly overexpressed on a broad range of solid tumors." These include brain, colon, non-small cell lung, melanoma, pancreatic and breast cancers. The patent includes claims covering composition of matter and methods of use. (PR) Comment! [Healthcare]
Monday, January 7, 8:02 AM ImmunoCellular Therapeutics (IMUC) provides an update about the various cancer vaccines it's developing, saying it expects the Data Safety Monitoring Committee to conduct an interim safety and futility analysis of the Phase IIb trial of ICT-107, which targets glioblastoma antigens and cancer stem cells, early this year. (PR) Comment! [Healthcare]
Monday, December 3, 2012, 5:48 PM After-hours top gainers, as of 5:15 p.m.: ESIO +11.7%. PETS +5.6%. DWA +5.2%. IMUC +3.2%. PACR +3%.
After-hours top losers: PBY -6.4%. PFPT -5.9%. DST -3.9%. PDLI -3.2%. GRMN -2.4%. Comment! [On the Move]
Monday, December 3, 2012, 4:23 PM ImmunoCellular (IMUC) +7% AH after announcing Andrew Gengos, until recently the CEO of private Neuraltus Pharmaceuticals, is its new CEO. Chief scientific officer John Yu had been serving as interim CEO since August, when former chief Manish Singh stepped down. Comment! [Healthcare, On the Move]
Thursday, October 18, 2012, 1:36 PM ImmunoCellular Therapeutics (IMUC -13.8%) slides after pricing its secondary offering of 10M shares at $2.10, a 13% discount to yesterday's close. The company also is offering warrants to purchase as many as 4.5M additional shares. It plans to use the proceeds for the ongoing clinical development of its brain cancer treatment and lead pipeline product, ICT-107, as well as for general corporate purposes. The company had 40.6 million shares outstanding as of August.
6 Comments [Healthcare, On the Move]
Thursday, October 18, 2012, 12:45 PM Midday top 10 gainers: CYBI +81%. OEH +26%. BWEN +23%. IESC +20%. ETH +20%. GIVN +18%. AEGR +17%. VIMC +16%. WCC +14%. CHCI +13.
Top 10 Losers: ALGN -24%. MNKD -23%. MLNX -21%. CYTR -19%. GORO -16%. IMUC -14%. RCON -13%. LXRX -11%. BCOM -11%. UFPI -11%. Comment! [On the Move]
Thursday, October 18, 2012, 9:10 AM Premarket gainers: GIVN +13%. WCC +11%. SVU +9%. JNPR +7%. NVAX +7%. MGM +6%. AEGR +5%.
Losers: MNKD -25%. CYTR -20%. ALGN -20%. IMUC -18%. LXRX -16%. MLNX -15%. GORO -14%. CDR -7%. SCSS -7%. VRNG -6%. 1 Comment [On the Move]
Thursday, September 6, 2012, 9:30 AM ImmunoCellular Therapeutics (IMUC) +19.3% premarket as Maxim Group begins coverage with a Buy rating and an $18 price target. The firm says IMUC has the potential to create a new, innovative second-generation dendritic cancer vaccine to address perceived shortfalls of Dendreon's (DNDN) Provenge. If successful, the firm thinks it could become a billion-dollar product. 5 Comments [Healthcare, Quick Ideas, On the Move]
Thursday, September 6, 2012, 9:10 AM Premarket gainers: IMUC +14%. MW +11%. OREX +10%. ARCT +8%. SHLD +7%. NAV +7%.
Losers: OCZ -30%. PAY -11%. WCRX -10%. Comment! [On the Move]
Tuesday, August 21, 2012, 9:10 AM Premarket gainers: DEXO +35%. URBN +16%. NDSN +10%. PRAN +7%. PSTI +6%.
Losers: IMUC -15%. BBY -10%. VHC -8%. Comment! [On the Move]

Robbster
Biotech holds include $ARQL, $CUR, $GALE, $IMUC, $NBS, $PSTI, $ STEM, $NLNK. Questioning ARQL, NLNK, but holding for now...
Mar 12, 10:21 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Brad Kenagy
BillMauer $KERX 24.26%,MattSchilling $IMUC 21.43%,Isreal Shenker $KNDI 6.99%,EWBarnaba $ZTS 4.92%,mktlab68 $SRPT 4.33% http://bit.ly/TrJs0h
Feb 9, 1:49 PM
Reply (2)

• !Report Abuse
View all 2 replies
jsiebel720: & the value added here is what ????
Feb 13, 6:09 PM
• !Report Abuse
Brad Kenagy: It's a contest I am running to see who can provide Alpha by posting a positive return,and beat the $SPY.The link has the contest details.
Feb 13, 6:52 PM
• !Report Abuse
Add a reply...

140 characters

BioInvestor2013
$IMUC ImmunoCellular Therapeutics !! ICT-107 leak rumors ,, if this come true IMUC shares Explode up over $10
Feb 7, 5:22 AM
Reply (5)

• !Report Abuse
View all 5 replies
John Rayhall: Rumors from where? Any link?
Feb 15, 9:24 PM
• !Report Abuse
hatvani: is it a rumor from you?? I don't think it's worth the time typing the 100 some characters.
Feb 16, 3:44 AM
• !Report Abuse
Add a reply...

140 characters

BioInvestor2013
$IMUC easy over $3,5 !!
Feb 7, 1:24 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Hoang6
$IMUC: be careful, dont get burned, do your dd!
Feb 6, 12:57 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
I did an article on $IMUC before, perhaps its time to mention it on a catalyst trade list?
Feb 5, 10:52 AM
Reply (1)

• !Report Abuse
View all 1 replies
lawal wasiu: well good mr scott
Feb 6, 6:24 AM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Trade Alert: $IMUC price target opinion = $2.55 Catalyst = interim data + bullish chart @ http://bit.ly/12pZxK5
Feb 5, 10:17 AM
Reply (2)

• !Report Abuse
View all 2 replies
keiithc71: Looks like u already got this one nailed to. I wanted to get in but funds tied up elsewhere
Feb 6, 1:12 AM
• !Report Abuse
vdineshk: $2.55 is your price target with catalyst? Isnt that very low?
Feb 6, 2:06 AM
• !Report Abuse
Add a reply...

140 characters

Robbster
So, for those following, my total development biotech portfolio as of today: $ARQL, $CUR, $DNDN, $GALE, $IMUC, $NBS, $NLNK, $PSTI, $STEM.
Jan 3, 8:24 PM
Reply (1)

• !Report Abuse
View all 1 replies
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Jan 5, 3:09 PM
• !Report Abuse
Add a reply...

140 characters

Demetri Mallios
Down day for biopharma...reaction to $IMUC hiring a new CEO was a bit blunted, so I expect a nice pop in the coming days. $2.50?
12/4/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Demetri Mallios
Check out $IMUC. On the move again today. Up more than 20% from the time I wrote my highlight article.
11/29/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

BioInvestor2013
$IMUC ImmunoCellular Therapeutics !! ICT-107 leak rumors ,, if this come true IMUC shares Explode up over $10
Feb 7, 5:22 AM
Reply (5)

• !Report Abuse
View all 5 replies
John Rayhall: Rumors from where? Any link?
Feb 15, 9:24 PM
• !Report Abuse
hatvani: is it a rumor from you?? I don't think it's worth the time typing the 100 some characters.
Feb 16, 3:44 AM
• !Report Abuse
Add a reply...

140 characters

Brad Kenagy
BillMauer $KERX 24.26%,MattSchilling $IMUC 21.43%,Isreal Shenker $KNDI 6.99%,EWBarnaba $ZTS 4.92%,mktlab68 $SRPT 4.33% http://bit.ly/TrJs0h
Feb 9, 1:49 PM
Reply (2)

• !Report Abuse
View all 2 replies
jsiebel720: & the value added here is what ????
Feb 13, 6:09 PM
• !Report Abuse
Brad Kenagy: It's a contest I am running to see who can provide Alpha by posting a positive return,and beat the $SPY.The link has the contest details.
Feb 13, 6:52 PM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I did an article on $IMUC before, perhaps its time to mention it on a catalyst trade list?
Feb 5, 10:52 AM
Reply (1)

• !Report Abuse
View all 1 replies
lawal wasiu: well good mr scott
Feb 6, 6:24 AM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Trade Alert: $IMUC price target opinion = $2.55 Catalyst = interim data + bullish chart @ http://bit.ly/12pZxK5
Feb 5, 10:17 AM
Reply (2)

• !Report Abuse
View all 2 replies
keiithc71: Looks like u already got this one nailed to. I wanted to get in but funds tied up elsewhere
Feb 6, 1:12 AM
• !Report Abuse
vdineshk: $2.55 is your price target with catalyst? Isnt that very low?
Feb 6, 2:06 AM
• !Report Abuse
Add a reply...

140 characters

Robbster
So, for those following, my total development biotech portfolio as of today: $ARQL, $CUR, $DNDN, $GALE, $IMUC, $NBS, $NLNK, $PSTI, $STEM.
Jan 3, 8:24 PM
Reply (1)

• !Report Abuse
View all 1 replies
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Jan 5, 3:09 PM
• !Report Abuse
Add a reply...

140 characters

Robbster
My picks for my persona "Breakthrough Biotech Fund": PSTI, IMUC, (incumbents) GALE, NLNK, STEM (new additions). Up big on incumbents...
9/10/12
Reply (5)

• !Report Abuse
View all 5 replies
Robbster: PSTI has high expectations of revenue growth due to breakthrough disease treatments so incremental offering only suppressed price short term
9/20/12
• !Report Abuse
Robbster: So, even though each PSTI share now represents a lower percentage of the company, folks believe proceeds will be used to grow company faster
9/20/12
• !Report Abuse
Add a reply...

140 characters

jtank
IMUC down ~20% after CEO Singh resigns. I have no position in this company but have been waiting for awhile - now a buying opportunity?
8/20/12
Reply (3)

• !Report Abuse
View all 3 replies
Robbster: Agree this dip is buying opportunity. Trying to catch the bottom is always tricky... I'm buying soon, not sure if Wed. or Thursday.
8/21/12
• !Report Abuse
jtank: Today would have been a good day - I highly doubt it would dip below $2, no matter how panicked people get.
8/22/12
• !Report Abuse
Add a reply...

140 characters

doxno
Why is IMUC crashing today?
7/23/12
Reply (2)

• !Report Abuse
View all 2 replies
BaccoE: Bunch of large blocks that went off. Hoping someone is re-positioning their holdings and not selling cause of info.
7/23/12
• !Report Abuse
Robbster: Shorts who are coming up big loosers maybe?
7/23/12
• !Report Abuse
Add a reply...

140 characters

Brian Nichols
IMUC just announced its uplisting to AMEX
5/25/12
Reply (4)

• !Report Abuse
View all 4 replies
John Rayhall: It's skyrocketing today on good data.
5/31/12
• !Report Abuse
GVT: HI Brain - What is the price estimate for IMUC next week?,, do you expect a run over $4? - Thanks!
6/15/12
• !Report Abuse
Add a reply...

140 characters

johnjail
Just take a position in IMUC at 2.96 , so nice!
6/8/12
Reply (3)

• !Report Abuse
View all 3 replies
excalibur1: why such a drop today. what does mondays market hold. long imuc
6/8/12
• !Report Abuse
johnjail: imuc is a long run :)
6/12/12
• !Report Abuse
Add a reply...

140 characters

IMUC ImmunoCellular Therapeutics, Ltd.

IMUC

ImmunoCellular Therapeutics, Ltd.